Dyne Therapeutics' (DYN) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Dyne Therapeutics (NASDAQ:DYN - Free Report) in a research report released on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $45.00 price target on the stock.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. lowered Dyne Therapeutics from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Chardan Capital reissued a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Friday. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of Dyne Therapeutics in a research note on Friday. Piper Sandler reissued an "overweight" rating and set a $53.00 price objective on shares of Dyne Therapeutics in a report on Monday, September 23rd. Finally, StockNews.com cut shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $49.91.

Dyne Therapeutics Stock Down 1.9 %

DYN traded down $0.29 on Tuesday, reaching $15.00. The company had a trading volume of 2,327,226 shares, compared to its average volume of 2,522,078. Dyne Therapeutics has a 1 year low of $14.79 and a 1 year high of $47.45. The stock has a market capitalization of $1.53 billion, a PE ratio of -4.21 and a beta of 1.16. The stock has a 50-day moving average price of $26.77 and a 200-day moving average price of $33.88.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jason P. Rhodes sold 782 shares of the company's stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the transaction, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Dirk Kersten sold 23,671 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total value of $836,769.85. Following the transaction, the director now owns 99,652 shares in the company, valued at $3,522,698.20. This trade represents a 19.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,742 shares of company stock worth $1,443,246. 20.77% of the stock is owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in shares of Dyne Therapeutics by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company's stock valued at $3,655,000 after buying an additional 4,236 shares during the period. Virtue Capital Management LLC boosted its holdings in Dyne Therapeutics by 4.4% in the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company's stock valued at $834,000 after acquiring an additional 981 shares during the last quarter. Geode Capital Management LLC grew its position in Dyne Therapeutics by 4.8% during the third quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company's stock valued at $66,802,000 after acquiring an additional 84,760 shares during the period. Barclays PLC increased its stake in Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company's stock worth $7,446,000 after acquiring an additional 128,246 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Dyne Therapeutics in the 3rd quarter worth about $1,067,000. Hedge funds and other institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.